Mitsubishi Tanabe aims high as it eyes shift to new products and markets
This article was originally published in Scrip
Despite falling far short of the goals of its last mid-term business programme, Japan's Mitsubishi Tanabe Pharma (MTP) has unveiled an ambitious new five-year management plan under which it is aiming for group operating profit of ¥100 billion ($1.30 billion) on net sales of ¥500 billion.
You may also be interested in...
Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA coronavirus vaccine.
Headquartered in both China and US, the new firm will help partners bring drugs to China and other Asian markets. Novavax licenses COVID-19 vaccine in Japan to Takeda, following previous week’s deal for the vaccine in India.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.